Platelet Patents (Class 424/532)
-
Publication number: 20110200642Abstract: Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells.Type: ApplicationFiled: December 18, 2008Publication date: August 18, 2011Applicant: REGENERATIVE SCIENCES, LLCInventor: Christopher J. Centeno
-
Patent number: 7901344Abstract: A method of treating irradiated tissue, such as for revascularizing and preventing or reducing wound healing complications in a human or other animal subject having cancer. The method comprises administering to the irradiated tissue a therapeutic composition comprising one or more of platelet rich plasma, platelet poor plasma or platelet concentrate. In some embodiments the complications sought to be prevented and/or reduced can include: fibrotic tissue, prolonged would drainage, hematomas, seromas, fistula formation infection, pain, poor coloration, deficient vascularity, and desensitization in or around the irradiated site.Type: GrantFiled: May 9, 2008Date of Patent: March 8, 2011Assignee: Biomet Biologics, LLCInventor: John Yoo
-
Publication number: 20110052533Abstract: Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies.Type: ApplicationFiled: March 13, 2009Publication date: March 3, 2011Applicant: REGENERATIVE SCIENCES, LLCInventor: Christopher J. Centeno
-
Publication number: 20110027338Abstract: The invention provides composition and methods for repairing a ruptured anterior cruciate ligament.Type: ApplicationFiled: October 7, 2010Publication date: February 3, 2011Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Martha M. Murray, Michael F. Murray, Jennifer Marler
-
Publication number: 20110015586Abstract: This invention relates in general to a method and device for facilitating hemostasis and wound healing. In particular, the invention relates to the device comprising a polymeric material disposed on a scaffold that facilitates hemostasis and wound healing. Specifically, the invention contemplates the use of such scaffolds in conjunction with a negative pressure device.Type: ApplicationFiled: April 16, 2010Publication date: January 20, 2011Inventors: Dennis P. Orgill, Giorgio Pietramaggiori, Sergio Finkielsztein, John N. Vournakis
-
Publication number: 20100316727Abstract: Methods for therapeutic treatment of inflammatory conditions in a mammalian patient provide clinical benefits including reduction of inflammation, vasorelaxation, reduction in edema and increased blood flow, the methods generally comprising extracorporeal treatment of blood, blood fractionate, or other biological fluid to expose such fluids to a precise, measured amount of ozone to produce a blood or biological fluid having a quantified absorbed dose of ozone, and reinfusing the treated biological fluid to the patient to provide therapeutic effects beneficial in the treatment of inflammatory disorders and related symptoms or conditions.Type: ApplicationFiled: June 21, 2010Publication date: December 16, 2010Inventors: Joseph S. Latino, Steven A. Keyser
-
Patent number: 7838039Abstract: Provided are methods of applying biological compositions, that is, autologous bioadhesive sealant compositions containing one or more biological agents, to an individual, wherein all the blood components used in preparing the composition are derived from the patient who is to receive the biological composition. In one embodiment, the method comprises obtaining a whole blood sample from an individual; forming an inactive platelet rich plasma from the whole blood sample; mixing a biological agent into the inactive platelet rich plasma; obtaining thrombin from the whole blood sample; mixing the thrombin into the inactive platelet rich plasma to form a biological composition; and applying the biological composition to the individual.Type: GrantFiled: January 27, 2005Date of Patent: November 23, 2010Assignee: Arteriocyte Medical Systems, Inc.Inventors: Robert F. Baugh, Lisa M. Lim, Julie S. Johnston, John G. Rivera
-
Patent number: 7811607Abstract: The present relates to an autologous bioadhesive sealant composition or fibrin glue prepared by a two-phase method, wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied. A platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. In one embodiment, the platelet rich plasma is divided into two portions. In phase one, a compound that reverses the effect of the anticoagulant is added to the first portion and a clot is allowed to form. The clot is then triturated, and the resulting serum containing autologous thrombin is collected. In phase two, the serum obtained from phase one is mixed with the second portion of the platelet rich plasma to form the bioadhesive sealant of the present invention.Type: GrantFiled: December 3, 2004Date of Patent: October 12, 2010Assignee: Arteriocyte Medical Systems, Inc.Inventors: Robert F. Baugh, Lisa M. Lim, Julie S. Johnston, John G. Rivera
-
Publication number: 20100196442Abstract: A method for treating an open wound, such as a surgical wound, may include preparing a first composition including a platelet poor plasma (PPP), and preparing a second composition including a platelet rich plasma (PRP). A layer of the first composition may be applied within the open wound, and a layer of the second composition may be applied within the open wound over the layer of the first composition.Type: ApplicationFiled: April 13, 2010Publication date: August 5, 2010Inventor: Richard A. Hynes
-
Publication number: 20100178355Abstract: The present invention relates to a method for repairing or regenerating tissues in a patient such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, cardiac tissues and ulcers. The method comprises the step of administering simultaneously or sequentially a pro-coagulant factor and an effective amount of a polymer composition comprising a biocompatible polymer and blood or a component thereof. When the polymer composition is in contact with the pro-coagulant factor it is converted into a non-liquid state such that the polymer composition will adhere to the site in need of repair to effect repair of the tissue and/or regeneration thereof.Type: ApplicationFiled: November 30, 2007Publication date: July 15, 2010Inventors: Caroline D. Hoemann, Catherine Marchand
-
Publication number: 20100135969Abstract: Platelets are concentrated from the blood of a patient. The platelets are treated by a method such as ultrasound or agitation to obtain platelet releasate. This releasate as a whole or a component thereof is formulated into an injectable formulation which is administered to the same patient the platelets were extracted from in order to treat the patient's cancer.Type: ApplicationFiled: February 4, 2010Publication date: June 3, 2010Inventor: Allan Mishra
-
Patent number: 7678780Abstract: Platelets are concentrated from the blood of a patient. The platelets are treated by a method such as ultrasound or agitation to obtain platelet releasate. This releasate as a whole or a component thereof is formulated into an injectable formulation which is administered to the same patient the platelets were extracted from in order to treat the patient's cancer.Type: GrantFiled: December 23, 2004Date of Patent: March 16, 2010Inventor: Allan Mishra
-
Publication number: 20090074753Abstract: A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.Type: ApplicationFiled: November 25, 2008Publication date: March 19, 2009Inventor: Samuel E. LYNCH
-
Publication number: 20090053208Abstract: Methods and systems are disclosed for treating injured and/or ischemic tissue by delivering a platelet composition which induces neovascularization in the tissue and improves tissue perfusion.Type: ApplicationFiled: August 20, 2008Publication date: February 26, 2009Applicant: Medtronic Vascular, Inc.Inventor: ASHA NAYAK
-
Publication number: 20080286366Abstract: The invention is directed to platelets containing micron or nanometer size particles wherein the micron or nanometer sized particles comprises an active agent. The invention is also directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the above platelets. The invention is further directed to methods of delivering the micron or nanometer size particles containing an active agent to a site of interest in a patient.Type: ApplicationFiled: April 29, 2008Publication date: November 20, 2008Inventors: Thomas H. Fischer, E. Stan Eskridge, JR.
-
Publication number: 20080248083Abstract: Methods are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. In particular, a method of treating a cardiac tissue lesion is disclosed.Type: ApplicationFiled: June 17, 2008Publication date: October 9, 2008Applicant: Bioparadox, LLCInventor: Allan Mishra
-
Patent number: 7341873Abstract: There is provided a method for assessing the quality of platelet concentrates for determining their suitability for transfusion. More specifically dynamic light scattering measurements of the samples containing platelets are obtained and parameters, such as hydrodynamic radius and relative number of platelet-derived microparticles, are derived from these measurements that are indicative of platelet quality.Type: GrantFiled: August 24, 2004Date of Patent: March 11, 2008Assignee: Canadian Blood ServicesInventor: Elisabeth Maurer-Spurej
-
Patent number: 7202020Abstract: A platelet composition suitable for direct transfusion into a patient is provided. The platelet composition includes a preservation medium comprising plasma and a gel-forming material in a concentration relative to the plasma such that the medium is in a sufficiently fluent state at about 37° C. to allow platelets to move within the medium and is in a sufficiently gelatinous state at about 5° C. to substantially prevent platelets from moving freely within the medium; and platelets.Type: GrantFiled: June 9, 2004Date of Patent: April 10, 2007Assignee: Human BioSystemsInventors: David O. Lucas, Vladamir Serebrennikov
-
Patent number: 7169606Abstract: A protectant mixture for use in preserving biological materials comprising at least one polyhydroxy compound, and phosphate ions; a preservation medium comprising a biological material, at least one polyhydroxy compound, and phosphate ions; methods of preserving the preservation medium; and the resulting preserved biological material composition.Type: GrantFiled: March 12, 2004Date of Patent: January 30, 2007Assignee: Wisconsin Alumni Research FoundationInventors: Juan DePablo, Ying Nie, Sean P. Palecek
-
Patent number: 7112342Abstract: An improved platelet gel wound healant, and methods of preparation and use thereof for healing wounds are disclosed. The improved wound healant comprises a therapeutically effective amount of activated growth factors and ascorbic acid with optional one or more additional anti-oxidant such as vitamin A and/or E, and optional one or more antibiotics.Type: GrantFiled: January 30, 2003Date of Patent: September 26, 2006Assignee: Cytomedix, Inc.Inventor: Charles E. Worden
-
Patent number: 7094378Abstract: Methods and apparatuses for treating fluids to inactivate microorganisms which may be present therein, said fluid containing one or more components selected from the group consisting of protein, blood and blood constituents are provided. The methods comprise adjusting the percentage of plasma in said fluid to a desired value; mixing an inactivation-effective, substantially non-toxic amount of an endogenous photosensitizer or endogenously-based derivative photosensitizer to said fluid; exposing said fluid to photoradiation of sufficient wavelength and energy to activate the photosensitizer, whereby said microorganisms are inactivated.Type: GrantFiled: June 15, 2000Date of Patent: August 22, 2006Assignee: Gambro, Inc.Inventors: Raymond Paul Goodrich, Jr., Dennis Hlavinka
-
Patent number: 7011852Abstract: A method is described for separating, retrieving and concentrating platelets from whole blood relying on aggregation of the platelets followed by filtration. This method eliminates the need of a centrifuge for separating said cells from blood. To obtain cellular concentrates of platelets, blood is mixed with compatible agents that will aggregate cells while retaining contained growth factors. The resulting aggregates can then be separated from blood by filtration. If desired, the filter-captured aggregates are subject to a brief washing cycle where they are washed clean of residual aggregating agent, plasma, and red cells. Aggregates can then be partly or wholly deaggregated and the cells retrieved. The result is a suspension of cells and small aggregates with therapeutic levels of concentrated blood cells with included growth factors that are available for delivery to a wound site. A device that accomplishes the aforementioned process is also described.Type: GrantFiled: May 6, 2002Date of Patent: March 14, 2006Assignee: Hemogenesis, LLCInventors: Sivaprasad Sukavaneshvar, S. Fazal Mohammad
-
Patent number: 6942880Abstract: The present invention relates to the production of platelet gels formed into beneficial geometric shapes. Specifically the present invention provides a simpler way to introduce platelet gel for specific uses, such as into the cavity of a gum left after a tooth extraction. Molds of predetermined shapes are provided for forming the desired shape.Type: GrantFiled: April 9, 2001Date of Patent: September 13, 2005Assignee: Medtronic, Inc.Inventor: Victor D. Dolecek
-
Patent number: 6899813Abstract: A system for the production of a blood component composition is provided. The system includes a centrifuge having a blood reservoir for receiving and separating a blood sample into multiple components; a dispenser disposed outside of the centrifuge having a first collection chamber containing an activation agent and a second collection chamber containing one or more medicinal agents; means for removing a first portion at least one separated blood component from the centrifuge to the first container and a second portion to the second collection chamber, wherein the first collection chamber activates the first portion and stores the resulting clot and thrombin; a filter for separating the thrombin from the clot; and a nozzle for entraining and mixing the thrombin with the second portion containing the one or more medicinal components.Type: GrantFiled: December 17, 2003Date of Patent: May 31, 2005Assignee: Medtronic, Inc.Inventors: Victor D. Dolecek, Robert F. Baugh, John G. Rivera, William F. McKay, Jeffery C. Marx
-
Patent number: 6863829Abstract: For providing an anti-bacteria which is made from a natural material, therefore harmless if it is absorbed in the human body, can be produced in mass production with low cost, and shows a high anti-bacteria effect, the anti-bacteria agent is obtained by heating a shell in an atmosphere of inactive gas and burning the shell under the temperature which finally reaches 700° C.-2,500° C.Type: GrantFiled: August 12, 2002Date of Patent: March 8, 2005Assignee: Surfcera Co., Ltd.Inventors: Keiko Sasaki, Manabu Sasaki, Yukio Funai, Kasumi Koyama
-
Patent number: 6855489Abstract: Systems and methods treat plasma carrying contaminants and cellular matter that are capable of entraining contaminants. The systems and methods separate cellular matter from the plasma by filtration, thereby removing contaminants entrained within the cellular matter. The system and methods add to the plasma a photoactive material. The systems and methods emit radiation at a selected wavelength into the plasma to activate the photoactive material and thereby eradicate the contaminant that is free of entrainment by cellular matter.Type: GrantFiled: October 13, 2000Date of Patent: February 15, 2005Assignee: Baxter International Inc.Inventors: Robert E. Herman, John Chapman, Chong-Son Sun, Jean M. Mathias, Veronique Mayaudon, Serge de Gheldere, Daniel F. Bischof
-
Patent number: 6841170Abstract: A process is disclosed for preparing an autologous platelet gel and membranes thereof comprising mixing a platelet concentrate with a calcium salt and batroxobin. This process encompassing the use of batroxobin as the gel activator allows to overcome the prior art processes drawbacks connected with the use for the same purpose of human of bovine thrombin. A kit is also described for carrying out this process.Type: GrantFiled: December 13, 2000Date of Patent: January 11, 2005Inventors: Maria Cristina Sacchi, Marco Bellanda
-
Patent number: 6830762Abstract: The present relates to an autologous bioadhesive sealant composition or fibrin glue prepared by a two-phase method, wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied. A platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. In one embodiment, the platelet rich plasma is divided into two portions. In phase one, a compound that reverses the effect of the anticoagulant is added to the first portion and a clot is allowed to form. The clot is then triturated, and the resulting serum containing autologous thrombin is collected. In phase two, the serum obtained from phase one is mixed with the second portion of the platelet rich plasma to form the bioadhesive sealant of the present invention.Type: GrantFiled: June 18, 2002Date of Patent: December 14, 2004Assignee: Medtronic, Inc.Inventors: Robert F. Baugh, Lisa M. Lim, Julie S. Johnston, John G. Rivera
-
Patent number: 6828090Abstract: A platelet composition suitable for direct transfusion into a patient is provided. The platelet composition includes a preservation medium comprising plasma and a gel-forming material in a concentration relative to the plasma such that the medium is in a sufficiently fluent state at about 37° C. to allow platelets to move within the medium and is in a sufficiently gelatinous state at about 5° C. to substantially prevent platelets from moving freely within the medium; and platelets.Type: GrantFiled: March 11, 1999Date of Patent: December 7, 2004Assignee: Human BioSystemsInventors: David O. Lucas, Vladimir Serebrennikov
-
Patent number: 6723497Abstract: A dehydrated composition is provided that includes freeze-dried platelets. The platelets are loaded with trehalose which preserves biological properties during freeze-drying and rehydration. The trehalose loading is conducted at a temperature of from greater than about 25° C. to less than about 40° C., most preferably at 37° C., with the loading solution having trehalose in an amount from about 10 mM to about 50 mM. These freeze-dried platelets are substantially shelf-stable and are rehydratable so as to have a normal response to an agonist, for example, thrombin, with virtually all of the platelets participating in clot formation within about three minutes at 37° C.Type: GrantFiled: April 5, 2001Date of Patent: April 20, 2004Assignee: The Regents of the University of CaliforniaInventors: Willem F. Wolkers, John H. Crowe, Fern Tablin, Ann E. Oliver, Naomi J. Walker, Nelly Tsvetkova
-
Patent number: 6716187Abstract: A single-use system for separating blood and producing platelet concentrates includes an elongated container for receiving blood from a patient. The container has a movable plunger mounted within the blood container for expressing blood fractions separated during centrifugation of the container through a first port mounted at one end of said container, a second port mounted on the plunger, and a third port mounted on a plunger rod attached to the plunger.Type: GrantFiled: July 7, 2000Date of Patent: April 6, 2004Assignee: Implant Innovations, Inc.Inventors: Glen E. Jorgensen, Bruce Berckmans, III
-
Patent number: 6695805Abstract: Systems and methods treat plasma carrying contaminants and leukocytes that are capable of entraining contaminants. The systems and methods separate leukocytes from the plasma by filtration, thereby removing contaminants entrained within leukocytes. The systems and methods also add to the plasma a photoactive material and emit radiation at a selected wavelength into the plasma to activate the photoactive material and thereby eradicate the contaminant that is free of entrainment by leukocytes.Type: GrantFiled: May 5, 1998Date of Patent: February 24, 2004Assignee: Baxter International Inc.Inventors: Chong-Son Sun, John Chapman, Daniel F Bischof, Robert E Herman
-
Publication number: 20040022864Abstract: Devices and methods of delivering therapeutic agents to tissue are provided, which provide reduced outflow of therapeutic agents from an injection site. The methods include delivering one or more clot-promoting substances, such as platelets, fibrin and/or thrombin, to the injection site to entrap the therapeutic agent in the injection site. Devices include devices that are suitable for use in the provided methods.Type: ApplicationFiled: August 5, 2002Publication date: February 5, 2004Inventors: Toby Freyman, Maria Palasis, Wendy Naimark
-
Publication number: 20040013739Abstract: The invention concerns membrane fractions of cells containing a recombinant MGDG synthase and enriched with 1,2-sn-diacylglycerol, their preparation method, their use for screening molecules inducing MGDG synthase activity and a method for screening molecules inducing MGDG synthase activity using said membrane fractions.Type: ApplicationFiled: April 30, 2003Publication date: January 22, 2004Inventors: Eric Marechal, Stephane Miras, Jacques Joyard
-
Patent number: 6653063Abstract: A hematology control composition and method of making the composition is provided. The control employs a plurality of components including a synthetic plasma component, a red blood cell component, a platelet component and a leukocyte component. The leukocyte component includes at least one subpopulation having particles derived from other than white blood cells.Type: GrantFiled: June 8, 2001Date of Patent: November 25, 2003Assignee: Hematronix, Inc.Inventors: Frank J. Carver, James D. Lapicola
-
Patent number: 6649072Abstract: A novel method for producing an autologous platelet rich blood composition is described. The resulting blood composition is useful in procedures for enhancing bone fusion, hemostasis, and repairing soft tissue in animals.Type: GrantFiled: November 16, 2001Date of Patent: November 18, 2003Inventors: Robert Brandt, Michael Buzenius
-
Publication number: 20030198687Abstract: A method and composition for wound care is provided, the composition comprising autologous platelet-rich plasma that has been contacted with an activator.Type: ApplicationFiled: April 18, 2002Publication date: October 23, 2003Inventors: Keith Bennett, John H. Hartwig
-
Patent number: 6610291Abstract: The present invention relates to a ready-to-use ristocetin cofactor test reagent possessing long-term stability for use in coagulation tests.Type: GrantFiled: December 20, 2000Date of Patent: August 26, 2003Assignee: Dade Behring Marburg GmbHInventors: Jürgen Patzke, Konrad Braun
-
Patent number: 6599881Abstract: Antithrombotic materials and methods are provided for the treatment of thrombotic disorders, in which therapeutically effective amounts of BPI protein products are administered.Type: GrantFiled: July 6, 2000Date of Patent: July 29, 2003Assignee: Xoma CorporationInventors: Mark L. White, William Steve Ammons
-
Patent number: 6599724Abstract: The present invention relates to a pharmaceutical composition comprising Factor VIII and the divalent metal ions Zn2+ and Cu2+, optionally in the presence of Ca2+ ions and/or Mn2+ ions, wherein said Factor VIII is stable without the addition of albumin. The invention also relates to a method for the production of recombinant Factor VIII from mammalian cells carrying the gene therefor, comprising culturing said mammalian cells in medium free of plasma-derived protein and supplemented with divalent metal ions, including Cu2+ and Zn2+, and optionally in the presence of Ca2+ and Mn2+ ions.Type: GrantFiled: July 12, 2000Date of Patent: July 29, 2003Assignee: Biovitrum ABInventors: Marianne Mikaelsson, Helena Sandberg
-
Patent number: 6596180Abstract: A centrifuge system for the formation of an autologous platelet gel wherein all of the blood components for the gel are derived from a patient to whom the gel is to be applied. First a platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. The platelet rich plasma or platelet poor plasma is then automatically drawn out of the centrifuge bag and proportioned into separate chambers in a dispenser. The first portion is activated where a clot is formed and thrombin is obtained. The thrombin is then latter mixed with the second portion to obtain a platelet gel.Type: GrantFiled: April 9, 2001Date of Patent: July 22, 2003Assignee: Medtronic, Inc.Inventors: Robert F. Baugh, Lisa M. Lim, Julie S. Johnston, John G. Rivera, Victor D. Dolecek
-
Patent number: 6589759Abstract: The present invention describes novel compositions and methods to enhance the in vitro and in vivo production of platelets and/or proplatelets from megakaryocytes. The present invention describes compositions comprising megakaryocytes, nitric oxide donors (i.e. compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are substrates for nitric oxide synthase), and, optionally, at least one thrombopoiesis stimulating factor. The thrombopoiesis stimulating factor is preferably thrombopoietin. The nitric oxide donor is preferable S-nitrosoglutathione. The present invention also describes compositions comprising at least one nitric oxide donor and at least one thrombopoiesis stimulating factor. The present invention also provides methods for treating and/or preventing blood platelet disorders, and for producing platelets and/or proplatelets in vitro and in vivo.Type: GrantFiled: December 5, 2001Date of Patent: July 8, 2003Assignee: Trustees of Boston UniversityInventors: Joseph Loscalzo, Elisabeth M. Battinelli
-
Publication number: 20030007957Abstract: A wound care preparation free from bovine-derived activating agents is disclosed for use in wound care, for both topical wounds and surgical wounds. The preparation is isolated by first obtaining an amount of whole blood from the patient and treating the whole blood with one or more anti-clotting agents, subjecting the whole blood to a centrifugation process to obtain an amount of platelet-rich plasma, adding to the platelet-rich plasma an amount of anti-clotting neutralizing agent, and mixing the platelet-rich plasma with a structural matrix to increase viscosity of the preparation. In use, the viscous preparation can be applied directly to a wound or surgery incision and the viscous preparation may be mixed with other wound healing agents, growth matrices, or promoters such as anti-fungal agents, anti-biotic agents, and preservatives.Type: ApplicationFiled: July 3, 2001Publication date: January 9, 2003Inventors: Calvin Britton, Alex Dellinger, Jim Limbird, Carl Keller, Charles Worden
-
Patent number: 6444228Abstract: In general, the present invention relates to a two-phase method for forming an autologous bioadhesive sealant composition or fibrin glue wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied. First, a platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. The platelet rich plasma and platelet poor plasma are then divided into two portions. To the first portion, which is used in phase-one, a compound that reverses the effect of the anticoagulant is added, and a clot is allowed to form. The clot is then triturated and the resulting serum, containing autologous thrombin, is collected. The serum obtained from phase-one is then mixed with the second portion of the platelet rich plasma or platelet poor plasma, used in phase-two, to form the bioadhesive sealant of the present invention.Type: GrantFiled: April 20, 1998Date of Patent: September 3, 2002Assignee: Medtronic, Inc.Inventors: Robert F. Baugh, Lisa M. Lim, Julie S. Johnston, John G. Rivera
-
Publication number: 20020076445Abstract: A dehydrated composition is provided that includes freeze-dried eukaryotic cells. The eukaryotic cells are loaded with an oligosaccharide (e.g., trehalose) which preserves biological properties during freeze-drying and rehydration. The oligosaccharide loading is conducted at a temperature of from greater than about 25° C. to less than about 50° C., more preferably at about 35° C., with the loading solution having the oligosaccharide in an amount from about 10 mM to about 100 mM. These freeze-dried eukaryotic cells are rehydratable. A process for preserving and/or increasing the survival of dehydrated eukaryotic cells, including storing dehydrated eukaryotic cells having a residual water content greater than about 0.15 gram of water per gram of dry weight eukaryotic cells.Type: ApplicationFiled: August 9, 2001Publication date: June 20, 2002Inventors: John H. Crowe, Fern Tablin, Willem F. Wolkers, Ann E. Oliver, Naomi J. Walker, Thurein Htoo, Kamran Jamil
-
Patent number: 6362003Abstract: A method of quality control to diagnose the cause of a malfunction of an instrument. The method uses measurements of the physical property of a sample to diagnose the cause of a malfunction of an instrument. The spatial position of a control product sample is analyzed. Alternatively, the spatial position of a statistically significant number of patient blood samples can be used. The method enables the monitoring of an instrument for problems associated with debris and noise caused by red cell lysis inefficiency; instrument reagents pump volume settings; instrument laser alignments; instrument gain settings; and flow noise caused by partial plugs, residual plugs or other flow problems. The method provides a more specific indication of the type and cause of an instrument malfunctioning than non specific flagging provided by prior art methods.Type: GrantFiled: September 14, 1998Date of Patent: March 26, 2002Assignee: Coulter CorporationInventors: Carole Young, Michael Elliott, Nancy Naylor, Timothy J. Fischer
-
Publication number: 20020009500Abstract: A dehydrated composition is provided that includes freeze-dried platelets. The platelets are loaded with trehalose which preserves biological properties during freeze-drying and rehydration. The trehalose loading is conducted at a temperature of from greater than about 25° C. to less than about 40° C., most preferably at 37° C., with the loading solution having trehalose in an amount from about 10 mM to about 50 mM. These freeze-dried platelets are substantially shelf-stable and are rehydratable so as to have a normal response to an agonist, for example, thrombin, with virtually all of the platelets participating in clot formation within about three minutes at 37° C.Type: ApplicationFiled: August 23, 2001Publication date: January 24, 2002Inventors: Willem F. Wolkers, John H. Crowe, Fern Tablin, Ann E. Oliver, Naomi J. Walker, Nelly Tsvetkova
-
Publication number: 20020001624Abstract: The invention relates to a medicinal product for topical use for the promotion of wound healing, which comprises thrombocytes or thrombocyte fragments, wherein the thrombocytes or thrombocyte fragments contain growth factors and are capable of releasing the same and are present in the lyophilized or deep-frozen state and have been subjected to a process for virus partitioning and/or virus inactivation.Type: ApplicationFiled: July 12, 1999Publication date: January 3, 2002Inventors: FRIEDRICH BRAUN, HANS-PETER SPANGLER, JOHANN EIBL
-
Patent number: 6303152Abstract: A process is disclosed for the production of immune-genetically active suspensions of which the initial substances are fluids or tissues from the human or animal body. Autohemotherapy, immune-stimulatory and/or immune-suppressive effects are employed. The suspensions thus produced can be used as pooled sera as desired.Type: GrantFiled: March 15, 1993Date of Patent: October 16, 2001Inventor: Horst Kief
-
Publication number: 20010019819Abstract: A dehydrated composition is provided that includes freeze-dried platelets. The platelets are loaded with trehalose which preserves biological properties during freeze-drying and rehydration. The trehalose loading is conducted at a temperature of from greater than about 25° C. to less than about 40° C., most preferably at 37° C., with the loading solution having trehalose in an amount from about 10 mM to about 50 mM. These freeze-dried platelets are substantially shelf-stable and are rehydratable so as to have a normal response to an agonist, for example, thrombin, with virtually all of the platelets participating in clot formation within about three minutes at 37° C.Type: ApplicationFiled: April 5, 2001Publication date: September 6, 2001Inventors: Willem F. Wolkers, John H. Crowe, Fern Tablin, Ann E. Oliver, Naomi J. Walker